LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While our data affirm the role of TERT promoter mutations in glial tumors, effects on transcription and telomere length emphasise the importance of telomere biology in disease genesis and outcome.
|
25797251 |
2015 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Then, we also analyzed the impact of TERT promoter mutations, PTEN deletion, EGFR amplification and MGMT promoter methylation in diagnosis, prognosis and response to therapy in glioma molecular subgroup.
|
31623593 |
2019 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PubMed, Embase, and Web of Science were searched for articles on the association between TERT promoter mutations and survival of glioma patients until June 30, 2015.
|
26351078 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Intermediate survival was seen in patients with IDH1/2 mutant, but 1p/19q intact, mostly astrocytic gliomas, and in patients with IDH1/2 wild-type gliomas lacking the +7q/-10q genotype and TERT promoter mutation.
|
25783747 |
2015 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe the TERT promoter mutation spectrum according to the histological, genetic, and molecular subtypes of glioma, which may aid in glioma subtype classification and have clinical implications.
|
28868656 |
2017 |
LOC110806263
|
0.100 |
Biomarker
|
disease |
BEFREE |
The coexistence of BRAF and TERT promoter aberrations characterizes a subset of aggressive glioma.
|
31391125 |
2019 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hazard ratios from survival analysis of glioma patients were determined relative to the presence of TERT promoter mutations.
|
24937153 |
2014 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hot spot mutations in the promoter region of telomerase reverse transcriptase (TERT promoter mutations) occur frequently in tumors of neuroectodermal origin such as melanoma and glioma.
|
25035100 |
2014 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human telomerase reverse transcriptase (TERT) promoter mutations are important genetic alterations in many kinds of human malignancies, including glioma.
|
27230769 |
2016 |
LOC110806263
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to evaluate the status of TERT promoter and the respective prognostic significance in a cohort of 237 lower-grade gliomas comprising grades II and III astrocytomas, oligodendrogliomas, and oligoastrocytomas.
|
25081751 |
2015 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of telomerase reverse transcriptase (TERT) in gliomagenesis has been recently further strengthened by the frequent occurrence of TERT promoter mutations (TERTp-mut) in gliomas and evidence that the TERT SNP genetic rs2736100 influences glioma risk.
|
25314060 |
2014 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of our meta-analysis is to investigate the prognostic impact TERT promoter mutation in glioma patients and its interaction with other molecular markers, particularly Isocitrate Dehydrogenase (IDH) mutation from aggregate level data.
|
29198322 |
2017 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glioblastomas (GBM) exhibited the highest frequency of TERTp mutations (66.9%); in this glioma subtype, we found a significant association between TERTp mutations and poor prognosis, regardless of the population.
|
26914704 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study analyzed IDH and TERT promoter mutations in 295 WHO grade II and III diffuse gliomas treated with or without adjuvant therapies to explore their impact on the sensitivity of tumors to genotoxic therapies.
|
26314843 |
2015 |
LOC110806263
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increasing evidences have implicated somatic gain-of-function mutations at the telomerase reverse transcriptase (TERT) promoter as one of the major mechanisms that promote transcriptional activation of TERT and subsequently maintain telomere length in human cancers including glioma.
|
26556853 |
2016 |
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It allows in one run the molecular assessments required for the WHO classification of diffuse gliomas, including the recent recommendations to assess copy number alterations of chromosome 7 and 10, and of the TERT promoter region in IDHwt lower grade glioma.
|
30470264 |
2018 |